Cray - Investors - Overview
OVERVIEW
INVESTORS.CRAY.COM RANKINGS
Date Range
Date Range
Date Range
LINKS TO WEB PAGE
WHAT DOES INVESTORS.CRAY.COM LOOK LIKE?
INVESTORS.CRAY.COM HOST
PAGE TITLE
Cray - Investors - OverviewDESCRIPTION
Our supercomputing, storage and analytics products are designed to help you tackle the most challenging problems in science, engineering and business. CS Series Cluster Supercomputers. Sonexion Scale-out Lustre Storage System. Urika-XA Extreme Analytics Platform. Urika-GD Graph Discovery Appliance. Cray solutions enable accelerated discovery and problem solving across a range of industries, applications and budgets. Meet the company that has been leading the way in supercomputing for over 40 years. Cray .CONTENT
This website had the following in the site, "Our supercomputing, storage and analytics products are designed to help you tackle the most challenging problems in science, engineering and business." Our analyzers analyzed that the web page stated " Sonexion Scale-out Lustre Storage System." The Website also stated " Cray solutions enable accelerated discovery and problem solving across a range of industries, applications and budgets. Meet the company that has been leading the way in supercomputing for over 40 years."VIEW OTHER WEB PAGES
Raquo; Visit the main Crisis site. And get a social return on your investment. Similar to a company selling shares, Crisis is selling Investment Units. However, by using the money to help homeless people, there is a social return on investment. So, what is social return on investment? To establish our social return. How did we calculate this figure? Crisis encourage.
Reports Second Quarter 2015 Financial Results. Announces Conference Call to Discuss Second Quarter 2015 Results. There are currently no events scheduled.
Report of Organizational Actions - IRS form 8937. Friday, August 07, 2015. CubeSmart Second Quarter 2015 Earnings Call. Our strategy is to grow our property portfolio by being a consolidator in the highly fragmented self-storage industry. We believe these acquisitions will offer the Company economies of scale by spreading our management expertise and operating efficiency across a larger portfolio. We look to maximize the cash flow from our facil.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers. CUDC-907, an orally available small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.
7 Million, Up 15 Percent from Prior Year. Cynosure to Host Second-Quarter 2015 Financial Results Conference Call on July 28.